On the other hand, anti-B cell maturation antigen (BCMA) CAR-T cell therapy has been revealed to have desired activities in patients with relapsed or refractory multiple myeloma (MM) [57]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.